Investigation and outcomes in patients with nonspecific pleuritis: results from the International Collaborative Effusion database
- PMID: 37057081
- PMCID: PMC10086737
- DOI: 10.1183/23120541.00599-2022
Investigation and outcomes in patients with nonspecific pleuritis: results from the International Collaborative Effusion database
Abstract
Introduction: We present findings from the International Collaborative Effusion database, a European Respiratory Society clinical research collaboration. Nonspecific pleuritis (NSP) is a broad term that describes chronic pleural inflammation. Various aetiologies lead to NSP, which poses a diagnostic challenge for clinicians. A significant proportion of patients with this finding eventually develop a malignant diagnosis.
Methods: 12 sites across nine countries contributed anonymised data on 187 patients. 175 records were suitable for analysis.
Results: The commonest aetiology for NSP was recorded as idiopathic (80 out of 175, 44%). This was followed by pleural infection (15%), benign asbestos disease (12%), malignancy (6%) and cardiac failure (6%). The malignant diagnoses were predominantly mesothelioma (six out of 175, 3.4%) and lung adenocarcinoma (four out of 175, 2.3%). The median time to malignant diagnosis was 12.2 months (range 0.8-32 months). There was a signal towards greater asbestos exposure in the malignant NSP group compared to the benign group (0.63 versus 0.27, p=0.07). Neither recurrence of effusion requiring further therapeutic intervention nor initial biopsy approach were associated with a false-negative biopsy. A computed tomography finding of a mass lesion was the only imaging feature to demonstrate a significant association (0.18 versus 0.01, p=0.02), although sonographic pleural thickening also suggested an association (0.27 versus 0.09, p=0.09).
Discussion: This is the first multicentre study of NSP and its associated outcomes. While some of our findings are reflected by the established body of literature, other findings have highlighted important areas for future research, not previously studied in NSP.
Copyright ©The authors 2023.
Conflict of interest statement
Conflict of interest: J.M. Porcel is an associate editor of this journal. C.F.N. Koegelenberg declares honoraria for lectures from AstraZeneca and GlaxoSmithKline, in the 36 months prior to manuscript submission. All other authors declare no competing interests.
References
LinkOut - more resources
Full Text Sources